Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

By T. Jostock, J. Müllberg, S. Özbek, R. Atreya, Guido Blinn, N. Voltz, M. Fischer, Markus F. Neurath, S. Rose‐John. European Journal of Biochemistry, 2001

651 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ee9a286f4be86b5c1ffdf9841d3722de7ecce7a6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. S. Rose‐John
2. T. Hirano
3. Simon A. Jones
4. Luigi Ferrucci
5. M. Karin
6. Wan-Wan Lin
7. J. Scheller

In Oncology

1. S. Rose‐John
2. T. Hirano
3. Simon A. Jones
4. Neeraj Kumari
5. A. Bhatt
6. B. Dwarakanath
7. Asmita Das
8. S. Evans

In Radiology, Nuclear Medicine and Imaging

1. S. Rose‐John
2. Simon A. Jones
3. T. Hirano

Citations in the corpus

• The Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis (2014, background): “The gp130 protein is also present in the membrane form mgp130 and in soluble form sgp130 [111, 112].”
• Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. (2014, background): “In contrast, a soluble form of gp130 functions as an anti-inflammatory decoy receptor, blocking sIL-6R trans-signalling [53].”
• Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “Soluble gp130 acts as a natural antagonist of the IL-6–sIL-6R complex and an inhibitor for trans-signaling, but cissignaling is not affected (Jostock et al., 2001; Lemmers et al., 2009) (Fig.”
• Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61 (2005, background): “Soluble gp130 antagonism therefore distinguishes between activities coordinated by IL-6 trans-signaling and those controlled by IL-6 itself (3, 5, 10, 38).”
• Interleukin-6 in aging and chronic disease: a magnificent pathway. (2006, background): “The trans signaling mechanism is regulated by a soluble form of gp130 (sgp130), which can bind and completely inactivate the IL-6/sIL-6r complex (26,27) (Figure 3).”
• Interleukin-6 Family Cytokines. (2018, background): “Because IL-6 shows no measurable affinity to gp130, sgp130Fc did not affect IL-6 signaling via the membrane-bound IL-6R (classic signaling), but it efficiently blocked IL-6 trans-signaling (Jostock et al. 2001).”
• The Two Faces of IL-6 in the Tumor Microenvironment (2014, background): “On the other hand, soluble gp130 (sgp130) specifically antagonizes IL-6 trans-signaling without impeding classical signaling [12,17,19,22].”